Acute and Chronic Kidney Disease
[Acute and Chronic Kidney Disease]
EPTIS factsheet 1615596 | Last revision 2026-09-24 | URL: https://www.eptis.bam.de/pts1615596 https://www.eptis.bam.de/pts1615596
| PT provider | ||||||||||||||||||||||||||||||||||
| PT provider | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||||||||
| Based in | United Kingdom | |||||||||||||||||||||||||||||||||
| Language(s) | English | |||||||||||||||||||||||||||||||||
| Remarks | There are a number of elements to this Scheme (1) Creatinine for CKD (eGFR), (2) Creatinine for AKI, (3) Cystatin C and (4) KFRE pilot (KFRE is not accredited to ISO/IEC 17043:2023). The overall objective of all elements is to provide EQA for monitoring of renal assays and associated pathways. The Scheme provides EQA specimens targeted at specific Creatinine concentrations, with no other manipulation present. This allows wider investigation of Creatinine assays and how creatinine impacts eGFR equations and AKI pathways. This Scheme will test your eGFR equation and AKI algorithm in your LIMS. We would recommend that you have one registration per Creatinine assay as this will allow you to assess how any variation in Creatinine affects eGFR and AKI across your service. | |||||||||||||||||||||||||||||||||
| Keywords | ||||||||||||||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||||||||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||||||||||||||||||||
| Technical details | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||||||||||||||||||||
| Target group of participants | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||||||||
| Linked to specific legislation / standards | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||||||||
| Additional, subsidiary aims | Post market surveillance of testing methods | |||||||||||||||||||||||||||||||||
| Number of participants | ||||||||||||||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||||||||||||||||||||
| Fees and frequency | ||||||||||||||||||||||||||||||||||
| Participation fee | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||||||||
| Regularly operated | Yes (Monthly (11 per year)) | |||||||||||||||||||||||||||||||||
| Year of first operation | 2005 | |||||||||||||||||||||||||||||||||
| Contact details of the PT provider | ||||||||||||||||||||||||||||||||||
| Provider | Contact person | |||||||||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Phone: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Phone: +44 121 414 7300 Fax: Email: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.